Aclaris Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 24/100
What the filing says
Aclaris Therapeutics amended and restated its at-the-market (ATM) sales agreement with Leerink Partners and Cantor Fitzgerald on August 6, 2026. The agreement allows Aclaris to sell common shares up to the Maximum Program Amount (limited by registration statement size, authorized shares, Form S-3 rules, or prospectus scope). Agents receive a 3% selling commission. No specific dollar cap or share count is stated in the filing—the maximum is capped by regulatory/corporate constraints rather than a fixed amount.
Why this rating
ATM programs are routine for small-cap public companies; this is a second amended version, suggesting ongoing capital-raising flexibility. At ~$149M market cap, even a meaningful raise would be moderate. No deal economics, target use, or transaction size disclosed—purely a facility amendment.
Extracted items
- 2.02 results / earnings
- 8.01 other event
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.